Data Related to Chimerix's Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts related to the broad-spectrum antiviral compound CMX001 will be presented at the BMT Tandem Meetings being held February 13-17 in Salt Lake City. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).
Chimerix's presentations on CMX001 address the emerging safety profile of the compound and early clinical data on its activity against BK virus, and will be presented on Saturday, February 16 from 7:00 am to 5:00 pm MT:
Renal Safety of Broad Spectrum Antiviral CMX001 in the Prevention of CMV Infection Post ? Allogeneic Hematopoietic Cell Transplantation (HCT)
Monitoring Changes in Serum Albumin (SA) Concentrations as an Early and Objective Indicator of Potential CMX001 ? Associated Gastrointestinal (GI) Adverse Drug Effects
BK Virus ? Associated Nephropathy (BKVN), an Under ? Recognized Cause of Renal Dysfunction in Severely Immunosuppressed Hematopoietic Stem Cell Transplant (HSCT) Patients: Report of 5 Cases of BKVN and the Potential Role of CMX001 for Treatment
For more information, please see the BMT Tandem Meetings website: http://www.asbmt.org/displaycommon.cfm?an=3.
About Chimerix and CMX001
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens.
Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients. Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies. Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections. Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.
Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA).
Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.
SOURCE Chimerix, Inc.
CONTACT: Chimerix Contacts, Rebecca Heath, +1-919-972-7124, Elizabeth Kelly, +1-919-972-7109, or Media, Laura Bagby, +1-646-964-5852, email@example.com, or Investors, Rachel Hunter, +1-212-362-1200, firstname.lastname@example.org
Posted: February 2013